Vaccinex, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VCNX research report →
Companywww.vaccinex.com
Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.
- CEO
- Maurice Zauderer
- IPO
- 2018
- Employees
- 23
- HQ
- Rochester, NY, US
Price Chart
Valuation
- Market Cap
- $2.76M
- P/E
- -0.12
- P/S
- 4.59
- P/B
- -0.87
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -3117.30%
- Net Margin
- -3100.50%
- ROE
- 776.58%
- ROIC
- 760.66%
Growth & Income
- Revenue
- $601.00K · 5.44%
- Net Income
- $-18,634,000 · 7.98%
- EPS
- $-8.88 · 79.67%
- Op Income
- $-18,735,000
- FCF YoY
- 6.32%
Performance & Tape
- 52W High
- $1.50
- 52W Low
- $0.31
- 50D MA
- $1.00
- 200D MA
- $0.85
- Beta
- 0.56
- Avg Volume
- 2.18K
Get TickerSpark's AI analysis on VCNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 24 | FRIEDBERG ALBERT | other | 30,756 |
| Nov 14, 24 | FRIEDBERG ALBERT | other | 584,646 |
| Nov 14, 24 | Zauderer Maurice | other | 46,153 |
| Sep 18, 24 | Zauderer Maurice | other | 35,715 |
| Sep 18, 24 | Zauderer Maurice | other | 9,768 |
| Sep 18, 24 | Zauderer Maurice | other | 29,557 |
| Sep 18, 24 | Zauderer Maurice | other | 38,610 |
| Sep 18, 24 | Zauderer Maurice | other | 170,475 |
| Sep 18, 24 | Zauderer Maurice | other | 35,715 |
| Sep 18, 24 | FRIEDBERG ALBERT | other | 25,723 |
Our VCNX Coverage
We haven't published any research on VCNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VCNX Report →